Jenkem Technology Past Earnings Performance
Past criteria checks 2/6
Jenkem Technology has been growing earnings at an average annual rate of 14.1%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 3% per year. Jenkem Technology's return on equity is 7%, and it has net margins of 33.2%.
Key information
14.1%
Earnings growth rate
8.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 3.0% |
| Return on equity | 7.0% |
| Net Margin | 33.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Jenkem Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 271 | 90 | 0 | 3 |
| 31 Dec 23 | 299 | 123 | 0 | 0 |
| 30 Sep 23 | 331 | 122 | 60 | 56 |
| 30 Jun 23 | 364 | 144 | 60 | 63 |
| 31 Mar 23 | 399 | 182 | 61 | 72 |
| 31 Dec 22 | 407 | 187 | 64 | 77 |
| 30 Sep 22 | 410 | 199 | 66 | 79 |
| 30 Jun 22 | 410 | 207 | 66 | 79 |
| 31 Mar 22 | 382 | 192 | 61 | 67 |
| 31 Dec 21 | 351 | 176 | 58 | 54 |
| 30 Sep 21 | 323 | 172 | 45 | 42 |
| 30 Jun 21 | 277 | 139 | 43 | 35 |
| 31 Mar 21 | 230 | 111 | 38 | 28 |
| 31 Dec 20 | 187 | 86 | 30 | 26 |
| 30 Sep 20 | 167 | 77 | 31 | 30 |
| 30 Jun 20 | 148 | 70 | 26 | 24 |
| 31 Mar 20 | 139 | 66 | 26 | 22 |
| 31 Dec 19 | 134 | 62 | 26 | 21 |
| 31 Dec 18 | 101 | 36 | 24 | 13 |
| 31 Dec 17 | 77 | 21 | 21 | 11 |
Quality Earnings: 688356 has high quality earnings.
Growing Profit Margin: 688356's current net profit margins (33.2%) are lower than last year (45.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688356's earnings have grown by 14.1% per year over the past 5 years.
Accelerating Growth: 688356's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688356 had negative earnings growth (-50.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 688356's Return on Equity (7%) is considered low.